Global Transcatheter Market Outlook 2020

  • ID: 3618528
  • Report
  • Region: Global
  • 75 pages
  • RNCOS E-Services Private Limited
1 of 5
Increasing Focus on Transcatheter Mitral Valve Replacement

FEATURED COMPANIES

  • Direct Flow Medical, Inc.
  • Medtronic plc
  • St. Jude Medical, Inc.
  • Symetis SA
  • MORE
The ever increasing rise in the cardiovascular diseases, especially the valvular diseases, has led to the discovery of innovative treatment techniques. One of the recent technological innovations include the transcatheter heart valve replacement, which involves delivering the new replacement valves without removing the diseased valve via a catheter. This newly developed procedure thus eliminates the need of an open heart surgery. The technique has emerged to prove extremely beneficial for patients with high risk for the traditional open heart surgery. The success of these innovative techniques has garnered interest from major medical devices players from across the globe.

According to a new analysis in “Global Transcatheter Market Outlook 2020” report, the Global Transcatheter Heart Valve Replacement Market is valued at around US$ 1.8 Billion in 2015. The evolving market size could be attributed to factors such as rising incidences of valvular heart diseases, the increasing adoption of transcatheter aortic valve replacement as an alternate to the traditional open heart surgery, and the overall improving reimbursement scenario for this new procedure.

The report segments the market based on the types of transcatheter heart valves. The transcatheter aortic valve replacement accounted for the largest share in 2015. This high share of the market is attributed to large number of transcatheter aortic procedures in the US and Europe. Also, in terms of the route of delivery, the Transfemoral approach is the most preferred one, owing to the lower mortality rate and shorter recovery time.

In terms of geography, Europe is the largest market for the transcatheter heart valve replacement market. The large share of the European market is due less stringent regulatory environment in the region, which allows faster approval and commercialization of products in Europe as compared to other regions. However, it is the US market, which is expected to witness the highest growth, largely due to increasing regulatory approvals for the transcatheter heart valves, in addition to the increasing awareness of the technologically advanced technique. The report provides information on the current scenario, market outlook on the basis of the products available, application and geography, and the future forecasts on all prominent segments of the industry till 2020. Moreover, the report also provides information about the regulatory landscapes prevailing in different regions. The number of procedures performed for transcatheter aortic valve replacement is also analyzed in the report.

The report also provides details about the pipeline analysis of the various transcatheter heart valves, which are currently in the process of getting regulatory approvals in the US and Europe. The later part of the report focuses on competitive analysis of the key market players, in terms of their market share and their product offerings. Major players operating in this market include Edwards Lifesciences, Medtronic, St. Jude, amongst others. The competitive analysis is done at each player level, including their recent developments. To provide a thorough understanding of each player’s business model, the player’s current and historical financials have been analyzed. On the whole, the study included in the report provides a detailed market overview, current and future scenario, and industry trends which will likely generate key interest in investors thinking about joining the industry.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Direct Flow Medical, Inc.
  • Medtronic plc
  • St. Jude Medical, Inc.
  • Symetis SA
  • MORE
1. Analyst View

2. Research Methodology

3. Transcatheter Heart Valve Replacement - An Introduction
3.1 Types of Heart Valves
3.2 Heart Valve Diseases

4. Market Dynamics
4.1 Drivers
4.1.1 Rising Incidence of Valvular Heart Diseases
4.1.2 Increasing Adoption of Minimally Invasive Procedures
4.1.3 Favourable Reimbursement Scenario
4.1.4 Increasing Number of Transcatheter Aortic Valve Replacement Procedures
4.2 Challenges
4.2.1 Varied Stringency of Regulatory Procedures Delays Product Launches
4.2.2 Associated Risks with Transcatheter Aortic Valve Replacement
4.3 Opportunities
4.3.1 Increasing Focus on Transcatheter Mitral Valve Replacement
4.3.2 Expansion of Transcatheter Aortic Valve Replacement to Low and Intermediate Risk Patients

5. Global Transcatheter Heart Valve Replacement Market Outlook 2020
5.1 Current Market Size and Future Growth

6. Transcatheter Heart Valve Replacement Market, By Valve Type
6.1 Introduction
6.1.1 Transcatheter Aortic Valve Replacement
6.1.2 Transcatheter Pulmonary Valve Replacement

7. Transcatheter Heart Valve Replacement Market, By Delivery Route
7.1 Introduction
7.1.1 Transfemoral
7.1.2 Transapical

8. Transcatheter Heart Valve Replacement Market, By Region
8.1 Introduction
8.1.1 North America
8.1.1.1 Regulatory Landscape
8.1.2 Europe
8.1.2.1 Regulatory Landscape
8.1.3 Asia
8.1.3.1 Regulatory Landscape

9. Pipeline Analysis
9.1 US - Pipiline Analysis
9.2 Europe - Pipeline Analysis

10. Porter's Five Forces Analysis

11. Competitive Analysis
11.1 Market Share Assesment

12. Key Player Analysis
12.1 Boston Scientific Corporation
12.2 Direct Flow Medical, Inc.
12.3 Edward Lifesciences Corporation
12.4 JenaValve Technology, Inc.
12.5 Medtronic plc
12.6 St. Jude Medical, Inc.
12.7 Symetis SA

List of Tables
Table 6-1: Global - Transcatheter Heart Valve Replacement Market by Valve Type(Million US$), 2015
Table 7-1: Global - Transcatheter Heart Valve Replacement Market by Delivery Route (Million US$), 2015
Table 8-1: Global - Transcatheter Heart Valve Replacement Market by Region (Million US$), 2015
Table 12-1: Boston Scientific Corporation - Key Financials (Million US$), 2012-2014
Table 12-2: Boston Scientific Corporation - Product Portfolio for Transcatheter Heart Valve
Table 12-3: Direct Flow Medical, Inc. - Product Portfolio for Transcatheter Heart Valve
Table 12-4: Edward Lifesciences Corporation - Key Financials (Million US$), 2012-2014
Table 12-5: Edward Lifesciences Corporation - Product Portfolio for Transcatheter Heart Valve
Table 12-6: JenaValve Technology, Inc. - Product Portfolio for Transcatheter Heart Valve
Table 12-7: Medtronic plc - Key Financials (Million US$), 2013-2015
Table 12-8: Medtronic plc - Product Portfolio for Transcatheter Heart Valve
Table 12-9: St. Jude Medical, Inc. - Key Financials (Million US$), 2012-2014
Table 12-10: St. Jude Medical, Inc. - Product Portfolio for Transcatheter Heart Valve
Table 12-11: Symestis SA - Product Portfolio for Transcatheter Heart Valve

List of Figures
Figure 5-1: Global - Transcatheter Heart Valve Replacement Market (Million US$), 2015-2020
Figure 6-1: Global - Transcatheter Heart Valve Replacement Market by Valve Type (%), 2015
Figure 6-2: Global - Transcatheter Aortic Valve Replacement Market (Million US$), 2015-2020
Figure 6-3: Global - Transcatheter Pulmonary Valve Replacement Market (Million US$), 2015-2020
Figure 7-1: Global - Transcatheter Heart Valve Replacement Market by Delivery Route (%), 2015
Figure 7-2: Global - Transcatheter Heart Valve Replacement Market via Transfemoral Route (Million US$), 2015-2020
Figure 7-3: Global - Transcatheter Heart Valve Replacement Market via Transfemoral Route (Million US$), 2015-2020
Figure 8-1: Global - Transcatheter Heart Valve Replacement Market by Region (%), 2015
Figure 8-2: North America - Transcatheter Heart Valve Replacement Market (Million US$), 2015-2020
Figure 8-3: US - TAVR Procedures ('000), 2010-2015
Figure 8-4: Europe - Transcatheter Heart Valve Replacement Market (Million US$), 2015-2020
Figure 8-5: Europe - TAVR Procedures ('000), 2010-2015
Figure 8-6: Asia - Transcatheter Heart Valve Replacement Market (Million US$), 2015-2020 42
Figure 8-7: Asia - TAVR Procedures, By Country, 2014
Figure 10-1: Porter's Five Forces Analysis
Figure 11-1: Global - Market Share Assesment for Key Players, 2014 (%)
Figure 12-1: Boston Scientific Corporation - Break up of Revenue by Business Segments (%), 2014
Figure 12-2: Edward Lifesciences Corporation - Break up of Revenue by Product Group (%), 2014
Figure 12-3: Medtronic plc - Break up of Revenue by Operating Segments (%), 2015
Figure 12-4: St. Jude Medical, Inc. - Break up of Revenue by Product Group (%), 2014

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Direct Flow Medical, Inc.
  • Medtronic plc
  • St. Jude Medical, Inc.
  • Symetis SA
  • MORE
According to a new research report entitled, “Global Transcatheter Market Outlook 2020”, efforts are now being focused on the development of another structural heart procedure: transcatheter mitral valve replacement (TMVR).

With the efficacy of transcatheter aortic valve replacement, firmly established, there is an increased focus on the treatment of mitral valve disease.

The year 2015, witnessed some major, acquisitions; all aimed at the further development for the TMVR procedures. For instance, Edwards Lifesciences Corporation acquired CardiAQ Valve Technologies, Inc., a privately held company and developer of a transcatheter mitral valve replacement system. Similarly, Medtronic plc signed a definitive agreement to acquire Twelve, Inc., a privately-held medical device company focused on the development of a transcatheter mitral valve replacement (TMVR) device. Following the trend, Abbott Laboratories also completed the acquisition of Tendyne Holdings, Inc., a private medical device company focused on developing minimally invasive mitral valve replacement therapies. Tendyne's Bioprosthetic Mitral Valve System is designed to be implanted in a beating heart, without the need for open heart surgery, which would be a new treatment option for mitral valve replacement.

Major player like Edward Lifesciences, with their FORTIS trial, which involves the development of transcatheter mitral valve, is all ready to enter the market. Neovasc Inc. received an approval by the US FDA for the participating physicians to treat patients with its 40mm Tiara™ valve in the Company's TIARA-I Early Feasibility Trial. The TIARA-I Early Feasibility Trial is a multinational, multicenter trial to assess the safety and performance of Neovasc's Tiara™ Mitral Valve System and implantation procedure in high-risk surgical patients suffering from severe mitral regurgitation. Mitral valve disease is highly complex and requires multiple treatment options in order to tailor the therapy based on each person’s anatomy and health situation. This increased focus on TMVR will further lead to increase in the overall market.
Note: Product cover images may vary from those shown
5 of 5
- Boston Scientific Corporation
- Direct Flow Medical, Inc.
- Edward Lifesciences Corporation
- JenaValve Technology, Inc.
- Medtronic plc
- St. Jude Medical, Inc.
- Symetis SA

Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll